Adial Pharmaceuticals Expects To Appoint Celia Economides As CFO At Its Annual Meeting, Succeeding Vinay Shah

Ms. Economides brings more than two decades of experience in biotech finance, corporate development and capital markets. Over her career, she has helped execute more than $1 billion in equity financings, non-dilutive financings, and other strategic transactions. She joined Adial as Executive Vice President of Finance in August 2026.

Prior to joining Adial, Ms. Economides served as Chief Financial Officer and Chief Business Officer of CellCentric, a clinical-stage oncology company. Prior to that, she served as Executive Vice President and Chief Financial Officer of Gritstone bio, Inc. and later as interim Chief Executive Officer. Earlier in her career, she held senior roles at Kezar Life Sciences and Aurinia Pharmaceuticals, where she contributed to the development of small molecule drugs for autoimmune diseases. Ms. Economides also previously served as a director of global medical affairs at BioMarin Pharmaceutical, led investor relations at the Biotechnology Innovation Organization (BIO), and worked at a healthcare-focused hedge fund and in biotech-focused financial services. Ms. Economides holds a B.A. from McGill University and an M.P.H. in Health Policy and Management from Columbia University.